
SI-BONE Inc (SIBN) Stock Forecast & Price Target
SI-BONE Inc (SIBN) Analyst Ratings
Bulls say
SI-BONE Inc. demonstrated a robust financial performance in the second quarter of 2025, achieving a gross margin of 79.8%, reflecting an increase of approximately 80 basis points year-over-year. The company's revenue for the same period grew by around 23% year-over-year to $46.4 million, which is indicative of strong market demand and effective sales strategies, particularly as the number of engaged surgeons rose by approximately 25%. Furthermore, the revision of the 2025 revenue estimate to $196.5 million from $193.9 million highlights confidence in continued growth driven by enhanced sales productivity.
Bears say
The financial outlook for SI-BONE Inc reveals significant challenges, primarily due to sluggish growth in the global spine market, which has recently faced pricing pressures and procedural headwinds, resulting in growth rates in the low-single digits. Concerns are further compounded by potential reimbursement shifts from payors towards competitive products, which could lead to a decline in SI-BONE's market share within the sacroiliac joint fusion segment, negatively impacting revenue. Additionally, SI-BONE's EV/sales growth metric of 0.19x is substantially below the median of 0.34x for its growth peer group, indicating potential undervaluation relative to market expectations.
This aggregate rating is based on analysts' research of SI-BONE Inc and is not a guaranteed prediction by Public.com or investment advice.
SI-BONE Inc (SIBN) Analyst Forecast & Price Prediction
Start investing in SI-BONE Inc (SIBN)
Order type
Buy in
Order amount
Est. shares
0 shares